Kayne Anderson Rudnick Investment Management
MACK

Kayne Anderson Rudnick Investment Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-300
Closed -$4.43K – 1027
2024
Q1 		$4.43K Hold
300
– – ﹤0.01% 685
2023
Q4 		$4.02K Hold
300
– – ﹤0.01% 689
2023
Q3 		$3.7K Hold
300
– – ﹤0.01% 641
2023
Q2 		$3.69K Hold
300
– – ﹤0.01% 641
2023
Q1 		$3.69K Hold
300
– – ﹤0.01% 607
2022
Q4 		$3.44K Hold
300
– – ﹤0.01% 624
2022
Q3 		$1K Hold
300
– – ﹤0.01% 638
2022
Q2 		$2K Hold
300
– – ﹤0.01% 586
2022
Q1 		$2K Buy
+300
New +$1.69K ﹤0.01% 611

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's MACK Position: Q2 2024 in Review

Kayne Anderson Rudnick Investment Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 300 shares — an estimated $4.43K sold.

Kayne Anderson Rudnick Investment Management first reported a position in MACK in Q1 2022 and held it in 9 quarters. The position peaked at $4.43K in Q1 2024. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • Kayne Anderson Rudnick Investment Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 300 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $4.43K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2022 and held it in 9 quarters.
  • Kayne Anderson Rudnick Investment Management's Merrimack Pharmaceuticals, Inc. position peaked at $4.43K in Q1 2024.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.